Equity Vii L.P. Spectrum Sells 10,677 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

GoodRx Trading Up 1.7 %

GDRX stock opened at $7.99 on Thursday. The company has a debt-to-equity ratio of 0.96, a current ratio of 7.32 and a quick ratio of 7.32. The stock has a market capitalization of $3.00 billion, a price-to-earnings ratio of -799.00, a P/E/G ratio of 3.74 and a beta of 1.39. The business has a fifty day moving average price of $8.04 and a 200 day moving average price of $7.54. GoodRx Holdings, Inc. has a fifty-two week low of $4.14 and a fifty-two week high of $9.26.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The business had revenue of $200.60 million during the quarter, compared to the consensus estimate of $200.47 million. GoodRx had a negative net margin of 7.57% and a positive return on equity of 3.63%. The business’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.02 earnings per share. Analysts expect that GoodRx Holdings, Inc. will post 0.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on GDRX shares. Morgan Stanley increased their target price on shares of GoodRx from $7.00 to $9.50 and gave the company an “equal weight” rating in a research note on Monday, June 10th. TD Cowen lifted their price objective on GoodRx from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, May 16th. UBS Group cut their target price on GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research note on Friday, August 9th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target on shares of GoodRx in a research note on Friday, August 16th. Finally, Citigroup dropped their price objective on shares of GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $9.36.

Institutional Trading of GoodRx

Several hedge funds have recently modified their holdings of GDRX. GSA Capital Partners LLP acquired a new position in GoodRx during the 1st quarter worth $1,638,000. Rubric Capital Management LP bought a new stake in shares of GoodRx during the fourth quarter worth $39,348,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of GoodRx by 61.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 181,512 shares of the company’s stock valued at $1,289,000 after acquiring an additional 68,835 shares during the period. Jupiter Asset Management Ltd. bought a new position in GoodRx in the first quarter valued at about $707,000. Finally, Liontrust Investment Partners LLP acquired a new stake in GoodRx in the second quarter worth about $520,000. 63.77% of the stock is owned by institutional investors.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.